 |
Doug Macron is the editor of GenomeWeb's Gene Silencing News. He covers research and therapeutic applications of RNAi, miRNA, and other gene-silencing technologies. E-mail Doug Macron or follow his GenomeWeb Twitter account at @Genesilencing. |
NIH to Fund Nanoparticle-Based RNAi Cancer Drug Development, miRNA Biomarker Discovery
August 23, 2012
NIH to Fund Nanoparticle-Based RNAi Cancer Drug Development, miRNA Biomarker Discovery
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Rosetta Genomics, Prime Health Reach Deal for Coverage of MiRview Mets2 Assay
May 20, 2013 / GenomeWeb Daily News - NIH Awards $1.2M in Grants to Four Companies Developing RNAi, miRNA Cancer Drugs
October 4, 2012 / Gene Silencing News - Rosetta, Precision Therapeutics Reach Co-marketing Deal for miRview mets2 Assay
July 24, 2012 / GenomeWeb Daily News - NIH To Fund Projects to ID miRNA Cancer Markers, Study Role of ncRNAs in HIV-Associated Disorders
July 12, 2012 / Gene Silencing News - France's Theradiag Buys microRNA Diagnostics Shop Prestizia
June 28, 2012 / Gene Silencing News